The announcement of expected revenue growth in bioprocessing, supported by new alliances, suggests a positive outlook for STERIS. This could lead to a favorable short-term impact on the stock price, as investors may view the company's ability to grow despite macroeconomic challenges as a strong indicator of resilience and strategic planning.